X4 Pharmaceuticals (XFOR) EPS (Weighted Average and Diluted) (2020 - 2025)
Historic EPS (Weighted Average and Diluted) for X4 Pharmaceuticals (XFOR) over the last 6 years, with Q3 2025 value amounting to -$0.69.
- X4 Pharmaceuticals' EPS (Weighted Average and Diluted) rose 8740.88% to -$0.69 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.66, marking a year-over-year decrease of 212608.7%. This contributed to the annual value of -$0.19 for FY2024, which is 6727.9% up from last year.
- According to the latest figures from Q3 2025, X4 Pharmaceuticals' EPS (Weighted Average and Diluted) is -$0.69, which was up 8740.88% from -$3.47 recorded in Q2 2025.
- In the past 5 years, X4 Pharmaceuticals' EPS (Weighted Average and Diluted) ranged from a high of $13.57 in Q2 2024 and a low of -$7.77 during Q1 2024
- Its 5-year average for EPS (Weighted Average and Diluted) is -$0.49, with a median of -$0.33 in 2023.
- Over the last 5 years, X4 Pharmaceuticals' EPS (Weighted Average and Diluted) had its largest YoY gain of 421212.12% in 2024, and its largest YoY loss of 5470000.0% in 2024.
- Quarter analysis of 5 years shows X4 Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$1.28 in 2021, then skyrocketed by 84.38% to -$0.2 in 2022, then soared by 55.0% to -$0.09 in 2023, then plummeted by 120.06% to -$0.2 in 2024, then tumbled by 248.39% to -$0.69 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.69 for Q3 2025, versus -$3.47 for Q2 2025 and $0.04 for Q1 2025.